EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy

Xiaowu Sun iD, Joseph C Cappelleri, Laura L Lupton iD, Mary M Moran, Santiago M C Lopez, Laura Puzniak, Alon Yehoshua, Manuela Di Fusco

PLOS One · 25.03.2026 · 21 (3) · e0345639

DOI: 10.1371/journal.pone.0345639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 25.03.2026. Verfasst von Xiaowu Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Solutions, CVS HealthspireTM, CVS Health®, Wellesley, Massachusetts, United States of America. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Numerous grouping and scoring methodologies have been proposed to assess long COVID symptomatology. One approach is to use symptom count as a simple, quantifiable measure of long COVID symptom burden.

Methods

This was a secondary analysis of a nationwide patient-reported outcomes (PRO) study that recruited symptomatic adults testing positive for SARS-CoV-2 at a Retail Pharmacy in the spring of 2023. EQ-5D-5L TM , work productivity and impairment (WPAI), the Patient-Reported Outcomes Measurement Information System (PROMIS ® ) fatigue, and a long COVID symptom questionnaire were administered at Week 4, Month 3, and Month 6 after testing. Pre-infection EQ-5D-5L, WPAI, PROMIS fatigue were collected via recall. Cronbach’s α assessed internal consistency of symptoms. Scree plots determined number of significant factors (symptoms) to retain for analysis. Spearman correlation coefficients were calculated between number of symptoms and EQ-5D-5L, WPAI, PROMIS fatigue scores and their changes from pre-COVID baseline. Categorization of long COVID burden using number of symptoms was proposed based on scores via equipercentile linking.

Results

Of 505 patients, mean age was 46.3 years, 70.7% were female. Cronbach’s α was 0.865, denoting good internal consistency of the symptom survey instrument. The scree plot supported use of one factor for the composite 30-symptom list. Number of symptoms correlated strongly with EuroQol Utility Index (r = −0.53), presenteeism (r = 0.51), activity impairment (r = 0.51) and fatigue (r = 0.56). Statistically significant differences in mean number of symptoms were found between patients with versus those without problems in any of the 5 domains of the EQ-5-dimensional descriptive system. Based on linked PRO scores, subjects could be classified into low (≤2), medium (3–9), and high (≥10) symptom burden.

Conclusions

Number of long COVID symptoms correlated with validated PRO measures and identified three symptom-based categories of long COVID burden. Number of symptoms is a valid and internally consistent measure to assess long COVID burden in outpatient settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansFemaleSymptom BurdenMiddle AgedPost-Acute COVID-19 SyndromeAdultMaleSARS-CoV-2PharmaciesSurveys and QuestionnairesPatient Reported Outcome MeasuresQuality of LifeFatigue

Autor:innen und Institutionen

  • Life Sciences Solutions, CVS HealthspireTM, CVS Health®, Wellesley, Massachusetts, United States of America.
  • Statistical Research and Data Science Center, Pfizer Inc., Groton, Connecticut, United States of America.
  • MDSCA Vaccines, Pfizer Inc., Collegeville, Pennsylvania, United States of America.
  • Health Economics and Outcomes Research, Pfizer Inc., New York, New York, United States of America.

ORCID-Profile: Xiaowu Sun, Laura L Lupton

Förderung

  • Pfizer

Zitieren

APA

Sun, X., Cappelleri, J. C., Lupton, L. L., Moran, M. M., Lopez, S. M. C., Puzniak, L., Yehoshua, A., & Di Fusco, M. (2026). Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy. PLOS One, 21(3), e0345639. https://doi.org/10.1371/journal.pone.0345639

Vancouver

Sun X, Cappelleri JC, Lupton LL, Moran MM, Lopez SMC, Puzniak L, et al. Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy. PLOS One. 2026;21(3):e0345639. doi:10.1371/journal.pone.0345639

BibTeX
@article{Sun2026,
  author = {Sun, Xiaowu and Cappelleri, Joseph C and Lupton, Laura L and Moran, Mary M and Lopez, Santiago M C and Puzniak, Laura and Yehoshua, Alon and Di Fusco, Manuela},
  title = {Assessment of long COVID symptom burden in patients testing positive for SARS-CoV-2 at a nationwide retail pharmacy},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0345639},
  doi = {10.1371/journal.pone.0345639}
}
Kostenlos starten →